P39 Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double-Blind, Randomized, ...

THE cold weather can trigger a range of symptoms, with the most common being shivering. But if certain symptoms seem out of ...

Patients with chronic spontaneous urticaria experienced substantial reductions in hives and itch with briquilimab through 16 ...

I would have been bored, except the pain was so tiring that I could barely function. I spent the days shuffling around the ...

Secukinumab delivers sustained efficacy and quality of life improvements in pediatric generalized pustular psoriasis (GPP).

Citi keeps a Buy rating on Celldex (CLDX) with a $70 price target after after Jasper Therapeutics (JSPR) reported preliminary data from its ...

Analyst Silvan Tuerkcan of JMP Securities reiterated a Buy rating on Allakos (ALLK – Research Report), with a price target of $3.00.Stay Ahead ...

Rapid onset of deep and durable clinical responses observed across multiple dosing cohorts with a favorable safety profile ...

Despite the promising clinical data, the over 40% drop in Jasper's stock price indicates that investors may have reservations about the study results or the company's future prospects. As the market ...

Omalizumab biosimilar is under clinical development by Mabpharm and currently in Phase III for Chronic Urticaria Or Hives.

Medically reviewed by Jurairat J. Molina, MD Dermatitis is a group of skin problems related to genes, environment, and ...

The duration of CU is also unpredictable and disease control is often suboptimal, especially when treatment is inadequate. Chronic urticaria has a significant impact on work, even when it is well ...